NEW HAVEN: The board of The Towers has appointed Gus Keach as the new President/CEO of The Towers.
Keach has more than 40 years in the senior living industry in Connectciut, recently he was the Vice President, Senior Services at Community Renewal Team in Hartford.
According to the job posting for CEO “The mission of the Towers is to provide senior citizens of varying means with high quality living arrangements and services based upon Jewish values and traditions.”
The owner of a onetime Bridgeport food distribution business owner was sentenced to three years in jail, after being convicted in May of defrauding three restaurant companies of millions of dollars. CTPost article
HARTFORD: The CCIM [Certified Commercial Investment Member] Foundation has created the Wayne D’Amico Memorial Fund to recognize, D’Amico an Ivoryton resident and long time commercial realtor and CCIM member. D'Amico passed away on November 3 after a struggle with Pancreatic Cancer.
“Wayne was a great friend, an industry icon, as well as a great husband and father,” said CCIM Institute president Robin Webb..”
Business New Haven publisher, Mitchell Young said of D’Amico. “Wayne was a passionate and positive person and a great representative of the properties and communities he was working in and for. I never left a conversation with him not being better informed and feeling upbeat about progress in the region.”
NEW HAVEN: Neubert, Pepe & Monteith, P.C., has named Jane Ballerini has been named as a partner with the firm. According to the firm, Ballerini practices in the areas of commercial real estate law, commercial finance, and general commercial and business law. Neubert says, “Ballerini is one of only a few practicing U. S. Small Business Administration (SBA) Designated Attorneys in Connecticut and has developed a subspecialty in representing traditional lenders and Certified Development Companies in transactions involving government guaranteed loans including loans made under the SBA 504 and 7a loan programs.
“We are extremely pleased that Jane is now a partner at NPM,” said Andrew Lubin, principal. “She has dedicated herself to her clients and the profession with zeal and enthusiasm.”
HARTFORD: Guilford’s, Ryan Hanrahan has been appointed NBC Connecticut / WVIT First Alert Weather team’s new Chief Meteorologist. Ryan will deliver “real-time” weather forecasts for the station’s weekday evening newscasts from 4 p.m. to 6:30 p.m. and at 11 p.m.
Susan Tully, President and General Manager of NBC Connecticut, in announcing the promotion said. “Ryan delivers accurate, no-nonsense forecasts. I am confident he will thrive in this new role,” said. “His expertise and Connecticut roots blend to provide an unmatched knowledge that our viewers can trust.”
“Becoming a Chief Meteorologist in Connecticut has been a dream of mine since I was a kid growing up on the shoreline,” added Hanrahan. “I’m thrilled for this opportunity and excited to continue to share my love of weather and science with our viewers and in my home state.”
According to the station Hanrahan’s interest in weather was “sparked by the 1989 tornado in Hamden, as well as hurricanes Gloria and Bob. “
Ryan has a degree in Meteorology from Pennsylvania State University, at the NBC affiliate in Albany, New York, WNYT. Hanrahan first joined NBC Connecticut in 2005, after studying atmospheric science in graduate school at SUNY Albany. In 2016, he was awarded a New England Regional Emmy in the “Weather Anchor” category in recognition of his weather forecasts and coverage.
NEW HAVEN: Alexion Pharmaceuticals, Inc. [NASDAQ: ALXN] is adding some bioscience chops to its board appointing Francois Nader, M.D.
The company says “Nader is an accomplished leader in the biopharmaceutical industry with a proven track record of building and transforming companies, launching rare disease therapies, and creating significant shareholder value.”
Just last week in an editorial recognizing the gaps in Alexion’s board, Business New Haven, Conntact.com called for an expansion of bioscience experience on the board, as the company seeks to create a new drug pipeline, dependent on licensing and or acquisitions.